Economic Times
A new study published in The Lancet Gastroenterology and Hepatology reveals that Metabolic dysfunction-associated steatotic liver disease cases have surged globally, with 1.3 billion people affected in 2023, marking a 143 per cent rise since 1990. Based on data from the Global Burden of Diseases Study, the report projects that MASLD prevalence could reach 1.8 billion by 2050, driven by obesity, high blood sugar, and lifestyle changes linked to urbanisation.
Go to News Site